# A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19

> **NCT04672395** · PHASE2,PHASE3 · COMPLETED · sponsor: **Clover Biopharmaceuticals AUS Pty** · enrollment: 31454 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** CpG 1018/Alum-adjuvanted SCB-2019 vaccine
- **BIOLOGICAL:** Placebo; 0.9% saline
- **BIOLOGICAL:** SCB-2019 vaccine
- **BIOLOGICAL:** SCB-2019 vaccine for Placebo

## Key facts

- **NCT ID:** NCT04672395
- **Lead sponsor:** Clover Biopharmaceuticals AUS Pty
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-24
- **Primary completion:** 2022-09-15
- **Final completion:** 2023-04-23
- **Target enrollment:** 31454 (ACTUAL)
- **Last updated:** 2023-06-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04672395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04672395, "A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04672395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*